A big week for liver and kidney care: HHS launches a national kidney plan, FDA approves GSK's hep-B drug

A national plan for kidney care

The U.S. Department of Health and Human Services has launched the Kidney Care National Plan, describing it as a coordinated, department-wide strategy aimed at revitalizing kidney care in America. The initiative represents a federal-level effort to address long-standing challenges in how kidney care is organized and delivered. m:…9236

The department's framing is the whole point: rather than a single program, the plan is positioned as a comprehensive strategy cutting across HHS's operating divisions, with the stated goal of improving outcomes and care delivery for patients affected by kidney disease. Details of specific actions under the plan were thin in the announcement materials available, which means the plan's credibility will rest on what HHS's agencies actually do next — funding decisions, care-delivery changes and measurable targets. m:…9236

For a department whose health agenda has been pulled in multiple directions, a coordinated kidney strategy is a bid to show focus. Watch whether the plan produces concrete milestones in the coming months, and whether it connects to the department's other chronic-disease priorities. m:…9236

GSK's hep-B drug gets FDA approval

The U.S. Food and Drug Administration has approved Hibsago, the brand name for bepirovirsen, for the treatment of chronic hepatitis B virus infection. Bepirovirsen is described by the company as a first-in-class antisense oligonucleotide, the first of its kind approved for chronic hepatitis B. m:…9337

The approval covers adult patients without cirrhosis who have been on nucleos(t)ide analogue reverse transcriptase inhibitor therapy for at least six months, with suppressed HBV DNA and hepatitis B surface antigen levels of 3,000 IU/ml or below, in combination with that NrtI therapy. m:…9337

The company says the approval was supported by the B-WELL phase III trials, which it reports showed functional cure rates of 19% in adults with surface antigen levels at or below 3,000 IU/ml — compared with the current standard of care alone, which the company says typically achieves less than 1% functional cure after one year of treatment. Functional cure, in the company's definition, means HBV DNA and the HBsAg viral protein are undetectable for at least 24 weeks after stopping all treatment. The company describes the trials as global, multi-centre, randomised, double-blind, placebo-controlled studies conducted in 29 countries. m:…9337

GSK licensed bepirovirsen from Ionis Pharmaceuticals and collaborated with Ionis on its development. The drug is now approved in both Japan and the United States, and the company says it is advancing regulatory submissions in other geographies, with key decisions anticipated in the coming months. For patients facing lifelong therapy, the company is pitching a finite course with a real, if minority, chance of functional cure — a claim worth watching as real-world data accumulates. m:…9337

Kentucky posts hep-C trial results

Separately, results are now available for the Kentucky Viral Hepatitis Treatment Study, recorded as NCT03949764 on ClinicalTrials.gov. The study was a completed phase 4 clinical trial evaluating sofosbuvir/velpatasvir, sold as Epclusa, in patients with hepatitis C who also had opioid-related disorders and injection drug use. m:…7927

The study's sponsors, as recorded, included the National Institute on Drug Abuse and the National Cancer Institute alongside Gilead Sciences, the University of Kentucky, the Icahn School of Medicine at Mount Sinai and the University of Bristol. That sponsor list is itself the story: a federal-academic-industry collaboration aimed at a population that is often excluded from or underserved by clinical research — people with substance use disorders who carry hepatitis C. m:…7927

Taken together, the three developments point in the same direction: federal health institutions are putting weight behind organ-disease and viral-hepatitis agendas at the same time. HHS is reorganizing its kidney-care strategy, the FDA has cleared a first-in-class hepatitis B option whose key efficacy numbers come from the sponsor, and an NIH-recorded trial is publishing results on treating hepatitis C in one of the hardest-to-reach patient populations. The throughline is execution — whether the plan produces action, whether the drug's cure rates hold up outside trials, and what the Kentucky data says about treating the patients who need it most. m:…9236 m:…9337 m:…7927